The AlluraClarity system with its ClarityIQ technology provides high quality imaging for a comprehensive range of clinical procedures, achieving excellent visibility at low X-ray dose levels for patients of all sizes, a company release said.
The system’slow X-ray dose settings are a new development that will help clinicians to better manage their patients’ and their own exposure to X-ray radiation.
“All patients treated via X-ray guided interventions benefit from the advantage of low radiation exposure, but it is especially important when you are treating patients who have to undergo lengthy and complex procedures,” said Marco van Strijen, interventional radiologist at the St Antonius Hospital Utrecht/Nieuwegein, the Netherlands. “We have been using Philips’ AlluraClarity system for more than a year now and have really grown to appreciate the low dose settings. This technology is making a difference where it really matters.”
“The transition from highly invasive surgical procedures to minimally-invasive image-guided therapies, with all their intrinsic patient benefits, is a transformation in the delivery of healthcare that is rapidly accelerating around the globe,” said Gene Saragnese, CEO Imaging Systems at Philips Healthcare.
AlluraClarity was commercially introduced outside the USA in mid-2012, and since then more than 200 systems have been ordered. With this important milestone of FDA clearance, the system can now be marketed in the world’s largest healthcare market.
To reflect the cost pressures that modern hospitals and health systems face, ClarityIQ technology will also be available as an upgrade for the majority of Philips’ installed base of monoplane and biplane interventional X-ray systems.